Quest Diagnostics Acquires new AI-powered Platform

Quest Diagnostics partners with PathAI to revolutionise cancer diagnostics through AI and digital pathology, enhancing accuracy and speed in disease diagnosis and broadening access to expert consultations

Quest Diagnostics, a pioneering firm in diagnostic information services, has joined forces with PathAI, a leader in AI-powered pathology technologies, in a landmark deal that promises to reshape Quest’s approach to disease diagnostics. This strategic acquisition is set to enhance the precision, speed, and efficiency of cancer diagnostics and other diseases through advanced digital and AI pathology innovations.

Under the agreement, Quest will acquire select assets of PathAI Diagnostics, including its high-tech digital pathology lab based in Memphis, Tennessee. This facility will be transformed into Quest’s hub for AI and digital research and development, bolstering its specialty pathology divisions, AmeriPath and Dermpath Diagnostics. Meanwhile, PathAI will continue its focus on providing comprehensive clinical trial services to its biopharmaceutical clients.

The deal, expected to close in Q2 of 2024, also includes licensing arrangements for Quest to utilise PathAI’s AISight™, a state-of-the-art digital pathology image management system. This technology will be deployed across Quest’s extensive network of pathology labs and customer sites throughout the U.S.

Kristie Dolan, Senior Vice President of Oncology at Quest Diagnostics, emphasised the transformative potential of this collaboration. “AI and digital technologies have tremendous potential to improve cancer care, and Quest has the know-how to scale and deliver innovations that are high quality, efficient and broadly accessible. PathAI has industry-leading expertise in AI pathology innovation, and their state-of-the-art digitized laboratory in Memphis provides a platform for future growth,” Dolan stated.

The integration of digital pathology allows for the creation of high-resolution digital images of biopsy slides, which can be shared securely and quickly among pathologists nationwide. This technological advancement is particularly crucial as it addresses the growing need for expert consultations in areas with limited access to specialised pathologists and could significantly alleviate the current histotechnologist shortage by decentralising slide preparation.

Moreover, AI technology complements digital pathology by analysing these images to detect patterns indicative of cancer or other diseases, potentially leading to earlier and more accurate diagnoses.

The adoption of such technologies by a giant like Quest signifies a major shift in the anatomic pathology market. According to Andy Beck CEO of PathAI, “The relationship with PathAI and acquisition of PathAI Diagnostics will enable us to rapidly accelerate the adoption of digitization and artificial intelligence for our market”

The strategic acquisition also positions Quest to extend its reach in the diagnostic field, not only across the U.S. but also globally through its Global Diagnostic Network. The move could likely spur similar actions from other diagnostic manufacturers, who may feel the pressure to incorporate digital and AI technologies to remain competitive in a rapidly evolving healthcare landscape.

As the global burden of cancer continues to rise, with over 2 million new cases expected in the U.S. this year alone, the urgency for innovative diagnostic solutions has never been greater. Quest’s acquisition of PathAI Diagnostics represents a critical step forward in meeting this challenge, potentially setting a new standard for the industry in the era of digital and AI-driven healthcare solutions.

Staff Writer

Our in-house science writing team has prepared this content specifically for Lab Horizons

Leave a Reply

Your email address will not be published. Required fields are marked *